Applications

Potential pharmacological development of an InnoForm nanomaterial of API ‘X’ and an equivalent aqueous preparation using (A) an in vitro transwell model and (B) a pre clinical in vivo model, following a single oral dose. (C) Dose reduction strategy following multiple-doses in a pre clinical in vivo model. Examples of the methods employed and results for different APIs are described in McDonald et al., 2014; Giardiello et al 2016 and Savage et al., 2019.

Potential pharmacological development of an InnoForm nanomaterial of API ‘Y’ for long-acting parenteral (subcutaneous or intramuscular) delivery. (A) in vitro release rate of API ‘Y’ performed in biologically relevant simulating buffers (B) plasma exposure of API ‘Y’ in a pre-clinical in vivo model, following a single parenteral injection. Examples of the methods employed and results for different APIs are described in Bakshi et al., 2018; Tatham et al., 2019 and Hobson et al., 2019.

Bakshi et al., 2018

Tatham et al., 2019

Hobson et al., 2019

Tandem Nano Ltd (TNL) is a University of Liverpool UoL) start-up focussed on the development of its proprietary SDN (Solid Drug Nanoparticle) technology platform which has the potential to transform the delivery of active compounds in industries as diverse as pharmaceuticals to agrochemicals.

Join Our Mailing List

This form collects your name and email. For further information on how we protect and manage your submitted data please view our privacy policy.